Sterling Pharma Solutions expands presence in Japan

Koichi Hirayarma

Global API developer and manufacturer, Sterling Pharma Solutions, recently appointed Koichi Hirayarma to support it's presence in Japan following its 2017 growth in this market.

The contract development and manufacturing organisation (CDMO) now works with a number of clients in Japan, including two big pharma companies, providing services such as fluorination, hazardous chemistry and continuous processing.

Koichi Hirayarma has more than 40 years’ experience across the pharmaceutical, healthcare and chemical industries and has previously held positions at Johnson & Johnson and Showa Denko K.K.

His main responsibilities include driving Sterling’s sales activity in Japan and acting as a point of contact for the CDMO’s clients in this market.

Sterling’s technology and innovation strategy, which has seen them win two major contracts in Japan in 2017, is designed to ensure it is at the forefront of new developments in API manufacturing.

As part of this, the company works with a number of academic organisations on a several projects, including a fluorination project with Professor Graham Sandford at Durham University and a continuous processing project with John Blacker at Leeds University. It also works with specialist technology companies, including Prozomics and Nzomics Biocatalysis at Northumbria University.

Its partnerships with these organisations mean that Sterling can utilise their small-scale capabilities during proof of concept (POC) work, then scale-up and industrialise the processes to deliver APIs to market.

Kevin Cook, CEO of Sterling Pharma Solutions said: “Japan is the third largest pharmaceutical market in the world and in the last few years we have seen a lot of development in the innovator API space.”

“Sterling is strong when it comes to managing the challenges associated with innovator APIs and this is largely due to our commitment to developing and utilising new technologies to deliver complex molecules with quality output on time.”

“Japanese pharmaceutical companies have tended to manufacture most of their products in-house. However, with cost pressures continuing to increase and the growing emerging pharma sector in Japan; the outsourcing market is rapidly maturing to provide increasing opportunities for CDMOs.”

Koichi said: “The Japanese market is heavily concerned with quality, which is an area that Sterling excels in. The company’s regulatory compliance record, combined with access to the latest technologies, make Sterling an ideal service provider for Japanese companies. I look forward to continuing to grow its presence in this market.”

Sterling Pharma Solutions has been successfully audited by the Pharmaceutical and Medical Devices Agency (PDMA) in Japan.

Sterling’s site in the North East of England was founded in 1969 and has a strong heritage in API services. The CDMO is the UK’s largest provider of API development and manufacturing services to the pharmaceutical industry.

Companies